Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 5
Submit an article Journal homepage
2,452
Views
2
CrossRef citations to date
0
Altmetric
Coronavirus – Letters

COVID-19 vaccine associated transverse myelitis-Evusheld as an option when vaccination is not recommended due to severe adverse events

William E. FitzsimmonsDepartment of Pharmacy Systems, Outcomes and Policy, University of Illinois College of Pharmacy, Chicago, IL, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6189-5499View further author information
ORCID Icon
Article: 2068338 | Received 04 Apr 2022, Accepted 15 Apr 2022, Published online: 05 May 2022

References

  • Maroufi SF, Naderi Behdani F, Rezania F, Tanhapour Khotbehsara S, Mirzaasgari Z. Longitudinally extensive transverse myelitis after Covid-19 vaccination: case report and review of literature. Hum Vaccin Immunother. 2022 Mar 3:1–2. Advance online publication. doi:10.1080/21645515.2022.2040239.
  • Fitzsimmons W, Nance C. Sudden onset of myelitis after COVID-19 vaccination: an under-recognized severe rare adverse event (May 5, 2021). SSRN. https://ssrn.com/abstract=3841558.
  • Sriwastava S, Sharma K, Khalid SH, Bhansali S, Shrestha AK, Elkhooly M, Srivastava S, Khan E, Jaiswal S, Wen S. COVID-19 vaccination and neurological manifestations: a review of case reports and case series. Brain Sci. 2022;12(3):407. doi:10.3390/brainsci12030407.
  • Hirose S, Hara M, Koda K, Natori N, Yokota Y, Ninomiya S, Nakajima H. Acute autoimmune transverse myelitis following COVID-19 vaccination: a case report. Medicine (Baltimore). 2021;100(51):e28423. PMID: 34941191; PMCID: PMC8701778. doi:10.1097/MD.0000000000028423.
  • Cabral G, Gonçalves C, Serrazina F, Sá F. MRI negative myelitis induced by Pfizer-BioNtech COVID-19 vaccine. J Clin Neurol. 2022;18(1):120–22. PMID: 35021291; PMCID: PMC8762507. doi:10.3988/jcn.2022.18.1.120.
  • Alabkal J, Rebchuk AD, Lyndon D, Randhawa N. Incomplete subacute transverse myelitis following vaccination with Pfizer-BioNtech COVID-19 mRNA vaccine: a case report. Cureus. 2021 Dec 16;13(12):e20460. PMID: 35070526; PMCID: PMC8760850. doi:10.7759/cureus.20460.
  • Miyaue N, Yoshida A, Yamanishi Y, Tada S, Ando R, Hosokawa Y, Yabe H, Nagai M. Refractory longitudinally extensive transverse myelitis after severe acute respiratory syndrome coronavirus 2 vaccination in a Japanese man. Intern Med. 2022;61(5):739–42. Advance online publication. doi:10.2169/internalmedicine.8747-21.
  • Khan E, Shrestha AK, Colantonio MA, Liberio RN, Sriwastava S. Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature. J Neurol. 2022 Mar;269(3):1121–32. Advance online publication. doi:10.1007/s00415-021-10785-2.
  • Albokhari AA, Alsawas A, Adnan MH, Alasmari A, Aljuhani S, Almejalli M, Kedah H. Acute inflammatory transverse myelitis post-Pfizer-BioNtech-COVID-19 vaccine in 16-year-old. J Med Res Innov. 2021 Feb;5:47–50. doi:10.25259/JMRI_25_2021.
  • Eom H, Kim SW, Kim M, Kim YE, Kim JH, Shin HY, Lee HL. Case reports of acute transverse myelitis associated with mRNA vaccine for COVID-19. J Korean Med Sci. 2022;37(7):e52. PMID: 35191229; PMCID: PMC8860770. doi:10.3346/jkms.2022.37.e52.
  • Guarnaccia J, Creed M, Muriel S. Transverse myelitis as a first event of multiple sclerosis precipitated by Pfiizer=BioNTech COVID-19 vaccination. Neuroimmunol Rep. 2022;2:100074. doi:10.1016/j.nerep.2022.100074.
  • Caliskan I, Bulus E, Afsar N, Altintas A. A case with new-onset neuromyelitis optica spectrum disorder following COVID-19 mRNA BNT162b2 vaccination. Neurologist. 2022 Feb. PMID: 35184119. doi:10.1097/nrl.0000000000000420.
  • Fernandes J, Jaggernauth S, Ramnarine V, et al. Neurological conditions following COVID-19 vaccinations: chance or association? Cureus. 2022 ;14(2):e21919. doi:10.7759/cureus.21919.
  • McLean P, Trefts L. Transverse myelitis 48 hours after the administration of an mRNA COVID 19 vaccine. Neuroimmunol Rep. 2021;1:100019. doi:10.1016/j.nerep.2021.100019.
  • Tixagevimab and cilgavimab (Evusheld) for pre-exposure prophylaxis of COVID-19. Jama. 2022;327(4):384–85. doi:10.1001/jama.2021.24931.
  • Covid-19: evusheld is approved in UK for prophylaxis in immunocompromised people. Bmj. 2022;376. (Published 17 March 2022). doi:10.1136/bmj.o722.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.